title: Vernakalant for the conversion of atrial fibrillation: the new kid on the block?
abstract: Conversion of recent onset atrial fibrillation (AF) to sinus rhythm with antiarrhythmic drugs reduces the risk of hemodynamic instability, hospitalizations, and atrial remodeling seen with persistent AF. This is the main reason for pharmacological or electrical cardioversion to be considered first line of treatment for recent onset AF. Is there a role for new antiarrhythmic drugs in the conversion of AF as the first approach to a rhythm-control strategy? Vernakalant is a novel and relativity atrial selective drug which inhibits atrial-selective K(+) currents, with only a small inhibitory effect on the rapidly activating delayed rectifier K(+) current (IKr) in the ventricle. In this brief Review, we tell the journey of vernakalant to become an attractive alternative to achieve pharmacological cardioversion of AF.
authors.affiliation: Division of Cardiology, Cardiovascular Institute of Buenos Aires, Argentina.
authors.forename: Diego
authors.initials: D
authors.lastname: Conde
authors.forename: Adrian
authors.initials: A
authors.lastname: Baranchuk
mesh_terms: D000840:Anisoles / Q000009:adverse effects / Q000494:pharmacology*; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000494:pharmacology*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D006801:Humans; D011759:Pyrrolidines / Q000009:adverse effects / Q000494:pharmacology*; D016032:Randomized Controlled Trials as Topic
chemical_list: D000840:Anisoles; D000889:Anti-Arrhythmia Agents; D011759:Pyrrolidines; C524581:vernakalant
keywords: atrial fibrillation; pharmacological cardioversion; vernakalant
references.citation: Circulation. 2008 Mar 25;117(12):1518-25
references.pmid: 18332267
references.citation: Europace. 2012 May;14(5):666-74
references.pmid: 22223715
references.citation: Int J Cardiol. 2013 Oct 3;168(3):2423-5
references.pmid: 23518212
references.citation: Ann N Y Acad Sci. 2010 Feb;1188:78-86
references.pmid: 20201889
references.citation: Circ Arrhythm Electrophysiol. 2009 Dec;2(6):652-9
references.pmid: 19948506
references.citation: Europace. 2012 Oct;14(10):1385-413
references.pmid: 22923145
references.citation: Can J Cardiol. 2013 Oct;29(10):1330.e11-1330.e12
references.pmid: 23639270
references.citation: Europace. 2012 Jun;14(6):804-9
references.pmid: 22291438
references.citation: Cardiovasc Res. 2013 Apr 1;98(1):136-44
references.pmid: 23341577
references.citation: Am J Physiol Heart Circ Physiol. 2008 Oct;295(4):H1489-504
references.pmid: 18676686
references.citation: Cardiovasc Res. 2006 Jun 1;70(3):486-96
references.pmid: 16545351
references.citation: Circ Arrhythm Electrophysiol. 2012 Apr;5(2):400-8
references.pmid: 22322366
references.citation: Am J Cardiol. 2010 Nov 1;106(9):1277-83
references.pmid: 21029824
references.citation: Expert Opin Investig Drugs. 2007 Apr;16(4):519-32
references.pmid: 17371199
references.citation: Am Heart J. 2010 Jun;159(6):1095-101
references.pmid: 20569725
references.citation: J Am Coll Cardiol. 2011 Jan 18;57(3):313-21
references.pmid: 21232669
references.citation: Cardiovasc Res. 2013 Apr 1;98(1):145-54
references.pmid: 23341576
references.citation: Europace. 2014 Feb;16(2):162-73
references.pmid: 24108230
references.citation: J Cardiovasc Electrophysiol. 2005 Nov;16(11):1227-38
references.pmid: 16302909
references.citation: Circulation. 2007 Sep 25;116(13):1449-57
references.pmid: 17785620
references.citation: Lancet. 2010 Apr 3;375(9721):1212-23
references.pmid: 20334907
references.citation: Cardiovasc Ther. 2013 Dec;31(6):377-80
references.pmid: 23683253
references.citation: J Am Coll Cardiol. 2004 Dec 21;44(12):2355-61
references.pmid: 15607398
references.citation: Eur Heart J. 2010 Oct;31(19):2369-429
references.pmid: 20802247
references.citation: Int J Cardiol. 2013 Oct 9;168(4):4431-2
references.pmid: 23890913
references.citation: Heart Rhythm. 2008 Dec;5(12):1735-42
references.pmid: 19084813